An interventional study of Cooling Vest Procedure and Fasting overnight in Healthy Lifestyle, sponsored by Rockefeller University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 28 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Rockefeller University · Not applicable, Interventional, and Basic science
Brown adipose tissue (BAT) burns excess calories to produce heat in response to environmental cold. Rapidly growing evidence from rodent and human studies suggests that the presence and activation of brown fat are far more beneficial for whole body metabolism and cardiometabolic health than previously appreciated. Despite the clear associations between brown fat and metabolic health, we lack both: cost-effective means of detecting brown fat in humans as well as comprehensive insights into how brown fat facilitates metabolism on a molecular level in humans.
Emerging evidence suggests that the benefits of brown fat activation are mediated, at least in part, by secretion of specific molecules into the bloodstream which signal to metabolically active organs such as skeletal muscle, liver and brain. A number of these so-called brown adipokines (or BATokines) have now been discovered in mice and shown to positively impact glucose homeostasis, liver and muscle function. Human deep-neck brown fat biopsies reveal that >1000 molecules could potentially be secreted from brown fat, and >400 are released by human brown fat cells in a dish, representing a major opportunity for discovery of high translational value.
Here, we aim to identify a screen of first potential blood biomarkers of brown fat in healthy young humans. This will be achieved by analyzing plasma proteins in subjects with 'inactive brown fat' (warm) and 'activated brown fat' (3-hr cold exposure, cooling vests) using high-throughput technologies (SOMAscan and O-link) to identify temperature-sensitive brown fat-enriched molecules. This preliminary data will guide a larger follow up study in which we envision studying lean and obese (insulin sensitive and insulin resistant) subjects of various age groups and race/ethnicity. Human BATokines identified here will become primary targets for manipulation in experimental animals to assess their therapeutic potential against obesity, T2D, and associated diseases. Additionally, since current methods of brown fat detection in human rely on deep neck biopsies or costly 18-FDG-PET/CT scans, identification of blood biomarkers of brown fat would offer a cost-effective and non-invasive alternative for prediction of metabolic health in humans.
Fat plays a fundamental role in regulating metabolic health due to its capacity to store excess calories (white adipose tissue; WAT) or burn them to produce heat (brown adipose tissue, BAT). While white fat cells are located in deposits beneath the skin (subcutaneous) or around the internal organs (visceral) and expand with obesity, brown fat cells reside predominantly in the deep neck area and have evolved to turn fuel into heat (a process termed thermogenesis) when activated by environmental cold. This calorie-burning property of BAT suggest it is a type of 'good fat' which may protect us from conditions such as obesity. A wealth of mouse data confirms that activation of BAT via cold exposure provides significant health benefits to experimental animals, including protection from diet-induced obesity and improved glucose metabolism. BAT has only recently been detected in adult humans, which has led to efforts to understand its physiology and investigate whether its activity can be manipulated to treat metabolic diseases. Notably, in addition to storing or burning fat, adipose tissue secretes a large number of hormone-like factors into the bloodstream, known to affect blood glucose levels and insulin sensitivity (adiponectin, adipsin) as well as appetite and energy expenditure (leptin). Although many such factors have been identified in white fat, little is known about the proteins secreted from brown fat, particularly in humans.
In a recent study of 52,000 patients with 18-FDG-PET/CT scans to identify the presence of brown fat, we found that BAT+ individuals had significantly reduced odds of type 2 diabetes (T2D), coronary artery disease, and congestive heart failure, compared to matched individuals who did not have brown fat. A smaller independent study demonstrated that short-term activation of BAT with cooling jackets significantly improved insulin sensitivity in T2D patients. These findings collectively reveal that BAT carries extraordinary potential to impact metabolic health in humans.
Metabolic benefits linked with BAT cannot be explained by the generation of heat (thermogenesis) alone. Emerging evidence suggests that BAT secretes specific molecules into the bloodstream. A number of these so-called brown adipokines (or BATokines) have now been discovered in mice and shown to positively impact whole body glucose metabolism and liver function, reducing the susceptibility to metabolic disease. However, the 'secretome' of brown fat has not been well studied in humans, and hence the relevance of these BATokines to our physiology remains unclear. In support of this unexplored research avenue, gene expression data from deep-neck BAT biopsies reveal that >1,000 molecules could potentially be secreted from BAT in humans, and 431 were identified as being released from human BAT cells in a dish, but a comprehensive validation of these proteins in blood samples of participants with activated BAT is lacking.
The aim of this study is to identify a panel of plasma proteins induced by activation of brown fat in young healthy human participants and provide pilot data for a larger biomarker study. We will employ novel unbiased multiplex tools to identify up to 7,000 unique proteins of various abundances, in subjects before and after cooling. Using these data, we will be able to identify common circulating factors that correlate with BAT activation, and subsequently compare them with pre-existing gene expression data to find polypeptides secreted, shedded or otherwise released specifically by BAT. While this study will focus on the identification of proteins, we also have the potential to survey small molecule metabolites secreted into the circulation. This list of BATokines will become instrumental for validation and retro-translation of mouse data from our lab and the larger scientific community interested in the metabolic benefits conveyed by BAT. In addition to the discovery of potential therapeutic targets, the blood screen may become a valuable data platform for clinical biomarkers of brown fat. Since current methods of BAT detection in human rely on deep neck biopsies and/or costly 18-FDG-PET/CT scans, identification of blood factors that circulate proportionally to BAT activity or correlate with the presence or amount of BAT would offer a cost-effective, non-invasive alternative in human participants.
Rockefeller University is the lead sponsor of 123 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The cold vest procedure: The first blood draw will be taken from participants before the cooling procedure (time 0, 30mL blood). Participants will then be requested to put on hospital scrubs and the cooling vest will be placed on them. Since muscle shivering is an alternative way of heat production (skeletal thermogenesis), we will first determine individual 'shivering threshold' for each participant (coldest tolerable temperature; typically 14°C / 57.2F), based on participant-report and direct observation. The cold vest will then be kept on for 3 hours with a temp set to the coldest tolerable temperature (shivering threshold +2°C (\~16-17°C / 60.8F-62.6F) and body temperature will be monitored by a tympanic thermometer. Following 3 hours, 30mL of blood will be drawn (Time 180min). All participants will be re-warmed with blankets after cooling has been completed, and offered a warm drink and a snack.
Other: Cooling Vest Procedure
This arm has been added in order to exclude the effects of prolonged fasting on blood analytes. Previously enrolled participants will be re-invited to donate blood after 12hr fast and 3hrs later (15hr fast) without the cooling procedure. Participants will be re-consented for this lab appointment. The night prior the visit, the participants will be instructed to fast from 10:00pm. At the time of visit vital signs and anthropomorphic measurements will be taken. Blood Draw: The first blood draw will take place in the morning. Participant will then be asked to sit in the procedure room for 3 hours at room temperature; second blood draw will take place after 3 hrs. Total of 38ml of blood will be drawn. Blood will be used for clinical labs (fasting glucose, Hba1c, TSH, TG) and research.
Other: Fasting overnight
A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar\_CoolFlow\_Manual.pdf. Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation.
Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
Identification of cold-regulated blood proteome
Mass spectrometry generates a list of proteins for each sample. We will compare fold of change before and after cooling - a true change is defined as 1.5-fold.
Time frame: Before and after a 3 hour cooling procedure
Changes in HbA1c post cooling procedure using absorbance assay
Absorbance assay
Time frame: Before and after a 3 hour cooling procedure
Changes in insulin post cooling procedure using enzyme-linked immunosorbent assay (ELISA)
ELISA
Time frame: Before and after a 3 hour cooling procedure
Changes in triglycerides post cooling procedure using absorbance assay
Absorbance assay
Time frame: Before and after a 3 hour cooling procedure
Changes in TSH post cooling procedure using absorbance assay
Absorbance assay
Time frame: Before and after a 3 hour cooling procedure
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.